BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 17944913)

  • 1. LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer.
    Pattamadilok J; Huapai N; Rattanatanyong P; Vasurattana A; Triratanachat S; Tresukosol D; Mutirangura A
    Int J Gynecol Cancer; 2008; 18(4):711-7. PubMed ID: 17944913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
    Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
    Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer.
    Ma Z; Wang X; He J; Xia J; Li Y
    PLoS One; 2017; 12(3):e0174037. PubMed ID: 28355289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer.
    Häfner N; Steinbach D; Jansen L; Diebolder H; Dürst M; Runnebaum IB
    Int J Cancer; 2016 Jan; 138(1):217-28. PubMed ID: 26175272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter Hypermethylation of FANCF and Susceptibility and Prognosis of Epithelial Ovarian Cancer.
    Ding JJ; Wang G; Shi WX; Zhou HH; Zhao EF
    Reprod Sci; 2016 Jan; 23(1):24-30. PubMed ID: 26507869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HERV-K hypomethylation in ovarian clear cell carcinoma is associated with a poor prognosis and platinum resistance.
    Iramaneerat K; Rattanatunyong P; Khemapech N; Triratanachat S; Mutirangura A
    Int J Gynecol Cancer; 2011 Jan; 21(1):51-7. PubMed ID: 21330831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation.
    Sernbo S; Gustavsson E; Brennan DJ; Gallagher WM; Rexhepaj E; Rydnert F; Jirström K; Borrebaeck CA; Ek S
    BMC Cancer; 2011 Sep; 11():405. PubMed ID: 21943380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers.
    Lee YK; Park NH; Lee H
    Exp Mol Med; 2015 Nov; 47(11):e195. PubMed ID: 26584681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients.
    Akers SN; Moysich K; Zhang W; Collamat Lai G; Miller A; Lele S; Odunsi K; Karpf AR
    Gynecol Oncol; 2014 Feb; 132(2):462-7. PubMed ID: 24374023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer.
    Cao Q; Lu K; Dai S; Hu Y; Fan W
    Int J Clin Exp Pathol; 2014; 7(5):2392-401. PubMed ID: 24966949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients.
    Heinze K; Rengsberger M; Gajda M; Jansen L; Osmers L; Oliveira-Ferrer L; Schmalfeldt B; Dürst M; Häfner N; Runnebaum IB
    Clin Epigenetics; 2021 Jan; 13(1):15. PubMed ID: 33482905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRAME expression and promoter hypomethylation in epithelial ovarian cancer.
    Zhang W; Barger CJ; Eng KH; Klinkebiel D; Link PA; Omilian A; Bshara W; Odunsi K; Karpf AR
    Oncotarget; 2016 Jul; 7(29):45352-45369. PubMed ID: 27322684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential role and prognostic importance of dishevelled-2 in epithelial ovarian cancer.
    Liu R; Cheng J; Chen Y; Wang W; Chen J; Mao G
    Int J Gynaecol Obstet; 2017 Sep; 138(3):304-310. PubMed ID: 28513833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer.
    Wu Y; Zhang X; Lin L; Ma XP; Ma YC; Liu PS
    Asian Pac J Cancer Prev; 2014; 15(3):1171-6. PubMed ID: 24606436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LINE-1 hypomethylation is associated with a poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.
    Iwagami S; Baba Y; Watanabe M; Shigaki H; Miyake K; Ishimoto T; Iwatsuki M; Sakamaki K; Ohashi Y; Baba H
    Ann Surg; 2013 Mar; 257(3):449-55. PubMed ID: 23023202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression.
    Vermeij R; de Bock GH; Leffers N; Ten Hoor KA; Schulze U; Hollema H; van der Burg SH; van der Zee AG; Daemen T; Nijman HW
    J Immunother; 2011; 34(6):516-23. PubMed ID: 21654520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer.
    Hsu KF; Shen MR; Huang YF; Cheng YM; Lin SH; Chow NH; Cheng SW; Chou CY; Ho CL
    Br J Cancer; 2015 Jul; 113(3):414-24. PubMed ID: 26158423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction value of intercellular adhesion molecule-1 gene polymorphisms for epithelial ovarian cancer risk, clinical features, and prognosis.
    Cai G; Ma X; Zou W; Huang Y; Zhang J; Wang D; Chen B
    Gene; 2014 Aug; 546(1):117-23. PubMed ID: 23933413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic values of 5-hmC, 5-mC and TET2 in epithelial ovarian cancer.
    Zhang LY; Li PL; Wang TZ; Zhang XC
    Arch Gynecol Obstet; 2015 Oct; 292(4):891-7. PubMed ID: 25827305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage.
    Woloszynska-Read A; Zhang W; Yu J; Link PA; Mhawech-Fauceglia P; Collamat G; Akers SN; Ostler KR; Godley LA; Odunsi K; Karpf AR
    Clin Cancer Res; 2011 Apr; 17(8):2170-80. PubMed ID: 21296871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.